Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/59396
Type: Artigo de periódico
Title: Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy
Author: Nanda, K
Amaral, E
Hays, M
Viscola, MAM
Mehta, N
Bahamondes, L
Abstract: Objective: To evaluate the effect of an antiretroviral (ARV) therapy regimen containing zidovudine (AZT), lamivudine (3TC), and efavirenz (EFV) on the pharmacokinetics of depot medroxyprogesterone acetate (DMPA). Design: Open-label, nonrandomized, clinical trial. Setting: University hospital clinic. Patient(s): Thirty HIV-infected women; 15 using ARV therapy (AZT, 3TC, and EFV) and 15 non-users of ARV therapy, followed biweekly for 12 weeks. Intervention(s): Single injection of DMPA (150 mg IM) for both groups. Main Outcome Measure(s): Pharmacokinetic parameters of DMPA by liquid chromatography with mass spectrometry, and ovulation by serum P. Result(s): Maximum serum concentrations of DMPA were reached at 14 days after injection. The area under the curve was similar in both groups, as were the minimum concentration, half-life, and clearance. Only I woman, not using ARV therapy, ovulated at 11 weeks after DMPA. Conclusion(s): Pharmacokinetics of DMPA were similar in HIV-infected women, regardless of ARV therapy use, suggesting that triple therapy with AZT, 3TC, and EFV is not likely to interfere with the contraceptive effectiveness of DMPA.
Subject: depot medroxyprogesterone acetate
contraception
HIV
antiretroviral therapy
pharmacokinetics
Country: EUA
Editor: Elsevier Science Inc
Rights: fechado
Identifier DOI: 10.1016/j.fertnstert.2007.07.1348
Date Issue: 2008
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
WOS000259943400006.pdf221.08 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.